Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Frost & Sullivan
JULY 19, 2021
Leveraging a leading suite of end-to-end biopharmaceutical development services covering patient-focused clinical trial design and decentralized clinical trial (DCT) strategies, the company has helped develop 198 of the 200 top-selling biopharmaceuticals in the market. About Parexel International Corporation.
Let's personalize your content